CAPR

Capricor Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↓ 0/10
  • Momentum↑ 9/10
Capricor Therapeutics sales and earnings growth
CAPR Growth
Low
  • Revenue Y/Y↓ -52.08%
  • EPS Y/Y↓ -71.57%
  • FCF Y/Y↓ -78.40%
Capricor Therapeutics gross and profit margin trends
CAPR Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -736.60%
  • ROIC↓ -78.10%
Capricor Therapeutics net debt vs free cash flow
CAPR Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Capricor Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗